QIAGEN - QIAcuity Digital PCR Instruments

Michael Scheffler, Vice President and Head of PCR Business at QIAGEN discusses how the QIAcuity system helps biopharma customers meet their needs in drug discovery and development, including new cell and gene therapies; how QIAGEN works to customize assays for customers and provides access to tailored multiplex assays; and the benefits of digital PCR and how it can enhance drug safety and efficacy.
#QIAGEN
Michael Scheffler holds an MSc in Engineering from the Technical University Berlin, and a PhD from ETH Zurich, respectively. After graduating he joined a Swiss SME startup for five years, providing contract development services around medical device miniaturization, serving in the executive management as well as a board member. Now with QIAGEN for more than 15 years, Scheffler has held several R&D and program management positions. During this time he introduced several purification and detection platforms (QIAcube, RotorGene, QIAcuity) as well as regulated diagnostic applications into the market. Recently he took over responsibility for the Life Science PCR business.
Michael Scheffler, the Vice President and Head of PCR Business at QIAGEN, talks about how the QIAcuity system helps biopharmaceutical companies achieve their goals in drug discovery and development, particularly in the area of new cell and gene therapies. He also discusses how QIAGEN works with customers to customize assays and provide access to specialized multiplex assays, as well as the advantages of digital PCR in improving drug safety and effectiveness.
In this discussion, QIAGEN's Vice President and Head of PCR Business, Michael Scheffler, explains how the QIAcuity system supports biopharma customers in meeting their needs for drug discovery and development, including in the development of new cell and gene therapies. He also describes how QIAGEN customizes assays for customers and offers access to tailored multiplex assays, and highlights the benefits of digital PCR in enhancing drug safety and efficacy.
QIAGEN's VP and Head of PCR Business, Michael Scheffler, discusses the QIAcuity system and how it helps biopharma customers with drug discovery and development. He also talks about QIAGEN customizing assays for customers and providing access to specialized multiplex assays. Scheffler emphasizes the advantages of digital PCR for improving drug safety and efficacy.
In this discussion, the VP and Head of PCR Business at QIAGEN, Michael Scheffler, explains how the QIAcuity system helps biopharmaceutical companies with their drug research and development, including new cell and gene therapies. He also talks about how QIAGEN works with customers to make special assays and provides access to these assays, and highlights the benefits of digital PCR for improving drug safety and effectiveness.